Clinical trial NCT04490551 - References

Colorectal Cancer — Combining Risk Factors and Faecal Immunochemical Testing in Colorectal Cancer Screening: a Randomized Controlled Trial

Citation(s)

•   Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV
  Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70. Epub 2007 Sep 25.
•   Altman DG, Bland JM
  Statistics notes. Treatment allocation in controlled trials: why randomise? BMJ. 1999 May 1;318(7192):1209. Review.
•   Aniwan S, Rerknimitr R, Kongkam P, Wisedopas N, Ponuthai Y, Chaithongrat S, Kullavanijaya P
  A combination of clinical risk stratification and fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic participants. Gastrointest Endosc. 2015 Mar;81(3):719-27. doi: 10.1016/j.gie.2014.11.035.
•   Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F
  Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017 Apr;66(4):683-691. doi: 10.1136/gutjnl-2015-310912. Epub 2016 Jan 27.
•   Betés M, Muñoz-Navas MA, Duque JM, Angós R, Macías E, Súbtil JC, Herraiz M, De La Riva S, Delgado-Rodríguez M, Martínez-González MA
  Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol. 2003 Dec;98(12):2648-54.
•   Bevolkingsonderzoek Darmkanker Monitor 2017
  Erasmus MC en NKI / AvL; 2017
•   Cha JM, Lee JI, Joo KR, Shin HP, Park JJ, Jeun JW, Lim JU
  First-degree relatives of colorectal cancer patients are likely to show advanced colorectal neoplasia despite a negative fecal immunochemical test. Digestion. 2012;86(4):283-7. doi: 10.1159/000341738. Epub 2012 Oct 9.
•   Chang LC, Wu MS, Tu CH, Lee YC, Shun CT, Chiu HM
  Metabolic syndrome and smoking may justify earlier colorectal cancer screening in men. Gastrointest Endosc. 2014 Jun;79(6):961-9. doi: 10.1016/j.gie.2013.11.035. Epub 2014 Jan 25.
•   Colkesen EB, Ferket BS, Tijssen JG, Kraaijenhagen RA, van Kalken CK, Peters RJ
  Effects on cardiovascular disease risk of a web-based health risk assessment with tailored health advice: a follow-up study. Vasc Health Risk Manag. 2011;7:67-74. doi: 10.2147/VHRM.S16340. Epub 2011 Feb 9.
•   Cubiella J, Castro I, Hernandez V, González-Mao C, Rivera C, Iglesias F, Cid L, Soto S, de-Castro L, Vega P, Hermo JA, Macenlle R, Martínez A, Martínez-Ares D, Estevez P, Cid E, Herreros-Villanueva M, Portillo I, Bujanda L, Fernández-Seara J; COLONPREV study investigators
  Characteristics of adenomas detected by fecal immunochemical test in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1884-92. doi: 10.1158/1055-9965.EPI-13-1346. Epub 2014 Jun 24.
•   de Jong AE, Vasen HF
  The frequency of a positive family history for colorectal cancer: a population-based study in the Netherlands. Neth J Med. 2006 Nov;64(10):367-70.
•   de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AH, Stegeman I, Kraaijenhagen RA, Fockens P, van Leerdam ME, Dekker E, Kuipers EJ
  Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 2012 Oct;107(10):1570-8. doi: 10.1038/ajg.2012.249. Epub 2012 Jul 31.
•   Dekker N, van Rossum LG, Van Vugt-van Pinxteren M, van Stiphout SH, Hermens RP, van Zelst-Stams WA, van Oijen MG, Laheij RJ, Jansen JB, Hoogerbrugge N
  Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening. Eur J Cancer. 2011 Jul;47(10):1571-7. doi: 10.1016/j.ejca.2011.01.022. Epub 2011 Feb 28.
•   Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM
  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996 Nov 30;348(9040):1472-7.
•   Hewitson P, Glasziou P, Irwig L, Towler B, Watson E
  Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001216. Review.
•   Hewitson P, Glasziou P, Watson E, Towler B, Irwig L
  Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008 Jun;103(6):1541-9. doi: 10.1111/j.1572-0241.2008.01875.x. Epub 2008 May 13. Review.
•   Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O
  Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996 Nov 30;348(9040):1467-71.
•   Landelijke Monitoring en Evaluatie Bevolkingsonderzoek Darmkanker
  In: Milieu RvVe, ed.2019
•   Lynch HT, de la Chapelle A
  Hereditary colorectal cancer. N Engl J Med. 2003 Mar 6;348(10):919-32. Review.
•   Ma GK, Ladabaum U
  Personalizing colorectal cancer screening: a systematic review of models to predict risk of colorectal neoplasia. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1624-34.e1. doi: 10.1016/j.cgh.2014.01.042. Epub 2014 Feb 15. Review.
•   Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F
  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993 May 13;328(19):1365-71. Erratum in: N Engl J Med 1993 Aug 26;329(9):672.
•   Nederlandse Richtlijn Coloscopie Surveillance
  Nederlandse Vereniging van Maag-, Darm- en Levertartsen; 2013
•   Nguyen SP, Bent S, Chen YH, Terdiman JP
  Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009 Jun;7(6):676-81.e1-3. doi: 10.1016/j.cgh.2009.01.008. Review.
•   Protocol voor de toelating en auditing van coloscopiecentra en endoscopisten
  Rijksinstituut voor Volksgezondheid en Milieu; 2018
•   Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki MP, Butruk E
  Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006 Nov 2;355(18):1863-72.
•   Rex DK
  Quality in colonoscopy: cecal intubation first, then what? Am J Gastroenterol. 2006 Apr;101(4):732-4.
•   Robertson DJ, Imperiale TF
  Stool Testing for Colorectal Cancer Screening. Gastroenterology. 2015 Oct;149(5):1286-93. doi: 10.1053/j.gastro.2015.05.045. Epub 2015 May 30. Review.
•   Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Fléjou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H
  The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000 Aug;47(2):251-5.
•   Stegeman I, de Wijkerslooth TR, Stoop EM, van Leerdam ME, Dekker E, van Ballegooijen M, Kuipers EJ, Fockens P, Kraaijenhagen RA, Bossuyt PM
  Colorectal cancer risk factors in the detection of advanced adenoma and colorectal cancer. Cancer Epidemiol. 2013 Jun;37(3):278-83. doi: 10.1016/j.canep.2013.02.004. Epub 2013 Mar 9.
•   Stegeman I, de Wijkerslooth TR, Stoop EM, van Leerdam ME, Dekker E, van Ballegooijen M, Kuipers EJ, Fockens P, Kraaijenhagen RA, Bossuyt PM
  Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut. 2014 Mar;63(3):466-71. doi: 10.1136/gutjnl-2013-305013. Epub 2013 Aug 20.
•   Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S
  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004 Feb 18;96(4):261-8.
•   van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E
  Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008 Jul;135(1):82-90. doi: 10.1053/j.gastro.2008.03.040. Epub 2008 Mar 25.
•   Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C; Gastrointestinal Consortium Panel
  Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003 Feb;124(2):544-60.
•   Wong MC, Ching JY, Chan VC, Lam TY, Shum JP, Luk AK, Wong SS, Ng SC, Ng SS, Wu JC, Chan FK, Sung JJ
  Diagnostic Accuracy of a Qualitative Fecal Immunochemical Test Varies With Location of Neoplasia But Not Number of Specimens. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1472-9. doi: 10.1016/j.cgh.2015.02.021. Epub 2015 Feb 24.
•   Worthley DL, Smith A, Bampton PA, Cole SR, Young GP
  Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer. Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1079-83.
•   Yeoh KG, Ho KY, Chiu HM, Zhu F, Ching JY, Wu DC, Matsuda T, Byeon JS, Lee SK, Goh KL, Sollano J, Rerknimitr R, Leong R, Tsoi K, Lin JT, Sung JJ; Asia-Pacific Working Group on Colorectal Cancer
  The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. Gut. 2011 Sep;60(9):1236-41. doi: 10.1136/gut.2010.221168. Epub 2011 Mar 14.
•   Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, Fedato C, Saugo M, Dei Tos AP
  Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015 May;64(5):784-90. doi: 10.1136/gutjnl-2014-307508. Epub 2014 Sep 1.

Combining Risk Factors and Faecal Immunochemical Testing in Colorectal Cancer Screening: a Randomized Controlled Trial

Details for clinical trial NCT04490551